In recent weeks, major pharmaceutical companies (notably Pfizer) have signaled interest in selling prescription drugs directly to consumers, bypassing traditional intermediaries like pharmacies, pharmacy benefit managers (PBMs), and insurers. On its face, this appears to be a bold move to reduce markups and increase transparency — and perhaps to address public frustration over high drug prices.
However, when examining the underlying structure of U.S. prescription drug usage and costs, the prospects for significant savings appear limited. That’s because the vast majority of U.S. prescriptions are already filled with generic drugs, which tend to have much lower margins and fewer opportunities for further cost savings via distribution changes. Below is a breakdown of the data, along with the counterarguments.
The Generic Prescription Dominance
- According to the FDA’s Office of Generic Drugs, about 91% of all prescriptions dispensed in the U.S. are filled with generic drugs. U.S. Food and Drug Administration
- Reports from the generics advocacy group AccessibleMeds confirm that generic (and biosimilar) prescriptions account for roughly 90% of prescription volume. Association for Accessible Medicines+2Association for Accessible Medicines+2
- While generics dominate in volume, they account for a significantly smaller share of total spending. For example, in 2022, generics and biosimilars accounted for 17.5% of U.S. prescription drug spending. Association for Accessible Medicines
- Another source (AccessibleMeds) indicates generics account for about 13.1% of total drug costs (though this number may vary depending on definitions). Association for Accessible Medicines
- A RAND analysis found that U.S. prices for unbranded generic drugs (which represent ~90% of prescription volume) are already lower relative to other countries than brand-name drugs are — suggesting there is less “markup fat” to trim in the generics space. RAND Corporation
Because generics already make up the lion’s share of prescriptions, any cost-reduction strategy that primarily affects brand drugs will intrinsically be limited in its reach.
Why Direct-to-Consumer Doesn’t Automatically Mean Big Savings
Even if Pfizer (or any brand-name drugmaker) sells directly to consumers, several structural hurdles limit the potential savings:
- Limited Scope of Brand Drugs
The brand-name drugs that could benefit from DTC strategies are only a slice of total prescriptions — perhaps those still under patent protection or specialty medications. The bulk of everyday prescriptions are already generic. - Margins Are Tighter on Generics
Generic margins are significantly smaller than those of brand drugs. Distribution costs, logistics, and regulatory overhead still apply. There’s less “wiggle room” to cut out intermediaries and still maintain profitability. - Intermediaries & Rebates Complexity
PBMs, insurers, and rebate mechanisms are deeply woven into the U.S. drug payment system. Bypassing them may provoke resistance, renegotiations, or regulatory pushback. Also, some of the so-called markups are offset by rebates or cross-subsidizations that complicate the arithmetic of direct sales. - Price Compression Already in Effect
Once patent exclusivity ends, generic competition often drives the price of a drug class down to 20% or less of the original brand price within a few years. PMC+1 That rapid compression leaves less room for further cuts via new distribution channels. - Selective Drug Coverage
Direct-to-consumer models may only apply to a subset of drugs — perhaps flagship products or drugs where Pfizer can control branding and distribution. The impact on widely used generics or off-patent drugs may be minimal.
Real-World Example: The Pfizer / Trump Deal
In September 2025, Pfizer struck a deal with the Trump administration to sell certain medicines via a new platform (dubbed “TrumpRx”) at steep discounts for select drugs. The White House+3STAT+3Reuters+3
However, several analysts cautioned that:
- The scope of the affected drugs was limited. STAT
- Since many Americans already pay heavily discounted rates (via insurance, Medicare, Medicaid, etc.), direct discounts may not significantly shift the current cost burden. STAT
- The underlying structural issues with drug pricing and distribution remain unaddressed. STAT+1
In effect, this type of deal may result in headline-grabbing price cuts for specific brand medications — but it is unlikely to disrupt the broader system in a way that materially lowers costs across the board.
Potential Obstacles & Risks
- Regulatory pushback: Laws, regulations, and payer arrangements currently rely on numerous intermediaries, which is a complex and risky process.
- Limited scale: If direct sales account for only a fraction of total market activity, their bargaining power is accordingly limited.
- Supply chain & manufacturing constraints: Many generic active pharmaceutical ingredients (APIs) and manufacturing processes are imported or outsourced. For instance, a study reported that 83% of the top 100 prescribed generics are import-dependent. Coalition For A Prosperous America
- Drug shortages: Already, low-margin generics are more vulnerable to supply disruptions. Disrupting traditional supply chains may exacerbate shortages. Center for American Progress+1
Pfizer’s move (and similar forays by other brand drugmakers) into direct-to-consumer drug sales promises selective, incremental reductions in cost or margin for a subset of high-margin brand products. However, because 90% of prescriptions are already generic, and generics account for a much smaller share of spending, the overall upside for cost savings in the U.S. drug market is modest.
In other words: reinventing distribution for brand medicines is interesting. It may yield PR wins or niche savings, but it is unlikely — by itself — to fundamentally shift the economics of prescription drug spending in the U.S.
